MedTrace Logo

Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia

NCT00906945 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-04-04

Study results available
· View outcomes & findings →

Summary

This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.

Conditions

  • Leukemia, Myeloid, Acute

Interventions

DRUG

G-CSF

DRUG

Plerixafor

DRUG

Mitoxantrone

DRUG

Etoposide

DRUG

Cytarabine

Sponsors & Collaborators

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Geoffrey L. Uy, M.D. · Washington University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2012-11-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906945 on ClinicalTrials.gov